Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Non Operating Income (2023 - 2026)

Contineum Therapeutics' Non Operating Income history spans 4 years, with the latest figure at -$57000.0 for Q1 2026.

  • Quarterly Non Operating Income rose 56.15% to -$57000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $10.4 million through Mar 2026, up 132.5% year-over-year, with the annual reading at $8.1 million for FY2025, 5057.67% up from the prior year.
  • Non Operating Income came in at -$57000.0 for Q1 2026, down from $8.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $8.2 million in Q4 2025 to a low of -$167000.0 in Q2 2025.
  • The 4-year median for Non Operating Income is $291000.0 (2023), against an average of $1.5 million.
  • The largest YoY upside for Non Operating Income was 17536.17% in 2025 against a maximum downside of 2066.67% in 2025.
  • Contineum Therapeutics' Non Operating Income stood at -$47000.0 in 2023, then changed by 0.0% to -$47000.0 in 2024, then surged by 17536.17% to $8.2 million in 2025, then plummeted by 100.7% to -$57000.0 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Non Operating Income are -$57000.0 (Q1 2026), $8.2 million (Q4 2025), and $2.4 million (Q3 2025).